Subject is pregnant, or lactating, or of childbearing potential (to be considered of non-childbearing potential, a female must be post-menopausal for at least 1 year, surgically sterile, or using an effective method of contraception or abstinence from at least 4 weeks prior to the first vaccination and until at least 4 weeks after the last vaccination.
Participation in the 4 weeks preceding the first trial vaccination, or planned participation during the present trial period, in another clinical trial investigating a vaccine, drug, medical device, or medical procedure.
Previous history of receiving the rabies vaccine.
Previous history of receiving rabies immune globulin.
Any major psychiatric disorder, such as severe depression, severe anxiety disorder, psychosis, schizophrenia, other major psychiatric disorders, or seizures. History of mild depression or anxiety disorder that are well controlled are not exclusion criteria.
Use of any immunosuppressive drug at the time of the study or 30 days previously. Topical steroids will not be considered an immunosuppressive drug and their use will not be considered an exclusion criteria.
Any immunosuppressive disorder, such as HIV infection, common variable immunodeficiency, active cancers or chemotherapy.
History of renal insufficiency or requiring dialysis.
Have any condition that would, in the opinion of the site investigator, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol.
Identified as an employee of the Investigator or study center, with direct involvement in the proposed study or other studies under the direction of that Investigator or study center, as well as family members (i.e., immediate, husband, wife and their children, adopted or natural) of the employee or the Investigator.
Previous adverse reaction to any of the antimalarial drugs used in this study.

NCT02564471_exc_T3
Drug
rabies vaccine
NCT02564471_exc_T4
Drug
rabies immune globulin
NCT02564471_exc_T5
Observation
Previous history
NCT02564471_exc_T6
Observation
Previous history
NCT02564471_exc_T7
Condition
major psychiatric disorder
NCT02564471_exc_T8
Qualifier
severe
NCT02564471_exc_T9
Condition
depression
NCT02564471_exc_T10
Qualifier
severe
NCT02564471_exc_T11
Condition
anxiety disorder
NCT02564471_exc_T12
Condition
psychosis
NCT02564471_exc_T13
Condition
schizophrenia
NCT02564471_exc_T14
Condition
major psychiatric disorders
NCT02564471_exc_T15
Qualifier
other
NCT02564471_exc_T16
Condition
seizures
NCT02564471_exc_T17
Qualifier
mild
NCT02564471_exc_T18
Condition
depression
NCT02564471_exc_T19
Condition
anxiety disorder
NCT02564471_exc_T20
Negation
not
NCT02564471_exc_T21
Qualifier
well controlled
NCT02564471_exc_T22
Scope
depression or anxiety disorder
NCT02564471_exc_T23
Scope
severe depression, severe anxiety disorder, psychosis, schizophrenia, other major psychiatric disorders, or seizures
NCT02564471_exc_T24
Drug
immunosuppressive drug
NCT02564471_exc_T25
Temporal
at the time of the study
NCT02564471_exc_T26
Temporal
30 days previously
NCT02564471_exc_T27
Scope
at the time of the study or 30 days previously
NCT02564471_exc_T28
Drug
Topical steroids
NCT02564471_exc_T29
Negation
not
NCT02564471_exc_T30
Condition
immunosuppressive disorder
NCT02564471_exc_T31
Condition
HIV infection
NCT02564471_exc_T32
Condition
common variable immunodeficiency
NCT02564471_exc_T33
Temporal
active
NCT02564471_exc_T34
Condition
cancers
NCT02564471_exc_T35
Procedure
chemotherapy
NCT02564471_exc_T36
Scope
cancers or chemotherapy
NCT02564471_exc_T37
Scope
HIV infection, common variable immunodeficiency, active cancers or chemotherapy
NCT02564471_exc_T38
Condition
renal insufficiency
NCT02564471_exc_T39
Observation
History
NCT02564471_exc_T40
Procedure
dialysis
NCT02564471_exc_T41
Mood
requiring
NCT02564471_exc_T42
Scope
renal insufficiency or requiring dialysis
NCT02564471_exc_T45
Condition
adverse reaction
NCT02564471_exc_T46
Temporal
Previous
NCT02564471_exc_T47
Drug
antimalarial drugs
NCT02564471_exc_T48
Qualifier
used in this study